Brendan Delaney

Brendan Delaney is recorded as CEO and Board Member at Whitehawk Therapeutics, Inc. (WHWK) since January 1, 2023 and COO at Whitehawk Therapeutics, Inc. (WHWK). The newest filing on record that lists Brendan Delaney as COO at Whitehawk Therapeutics, Inc. (WHWK) is dated April 26, 2022. Whitehawk Therapeutics, Inc. reported in an 8-K filed March 3, 2023 that Brendan Delaney resigned as member of the Board of Directors, effective March 14, 2023. Whitehawk Therapeutics, Inc. reported in an 8-K filed March 3, 2023 that Brendan Delaney resigned as President and Chief Executive Officer, effective March 14, 2023. Whitehawk Therapeutics, Inc. reported in an 8-K filed November 9, 2022 that Brendan Delaney was appointed Class II director, effective January 1, 2023. Equibles holds 4 filed executive changes naming Brendan Delaney; each is listed under recent activity with its source filing. The proxy statement of Whitehawk Therapeutics, Inc. reports total compensation of $1,645,015 for Brendan Delaney in fiscal 2023, including a base salary of $128,000. Disclosed compensation is on record for 3 fiscal years. Whitehawk Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Whitehawk Therapeutics, Inc. includes David J. Lennon (CEO and Board Member), David Lennon (CEO and Board Member), Neil Desai, Ph.D. (CEO and Board Member) and 7 others.